Advertisement

Contraceptive vaginal rings releasing Nestorone�� and ethinylestradiol: a 1-year dose-finding trial

      Abstract

      In a multicenter 1-year trial of contraceptive vaginal rings (rings) involving 150 women, three dose combinations of the progestin Nestorone�� (NES) and ethinylestradiol (EE) were compared with respect to effectiveness, safety and acceptability. Mean in vitro drug release rates for the three doses were 150 and 15, 150 and 20 and 200 and 15 ��g/day of NES and EE, respectively. Each ring remained in situ for 21 days, removed for 7 days and then reinserted for a total of 13 cycles of use. We studied ring performance with respect to pregnancy and other termination events, adverse events, the extent of ovulation inhibition, serum drug levels and bleeding control. We also assessed the rings' effects on the vagina using a standardized colposcopy procedure.
      Seventy-two percent of the women completed the 1-year (���350 days) study. In studied cycles, luteal activity (progesterone ���10 nmol/L) was noted in 17%, 7% and 12% of subjects with monitored cycles at the 150/15, 150/20 and 200/15 doses, respectively (p=.34). Two pregnancies occurred, both in subjects using the 200/15 ��g/day ring. Breakthrough bleeding during ring use averaged about 2 days/year and breakthrough bleeding and spotting averaged about 7 days/year. In the entire trial, only two women discontinued because of bleeding problems. Medical conditions, chiefly vaginal problems, personal reasons and device loss or repeated expulsion were the principal reasons given for study discontinuation. Vaginal and cervical colposcopy, conducted with standardized techniques and standardized interpretations, revealed no elevated event incidence attributable to ring use. Clinical performance and adverse event profiles indicate that each of these 1-year NES/EE rings, used on a 21-day-in and 7-day-out regimen, provided women effective, acceptable and safe long-acting contraception under their own control.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Contraception
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Alvarez-Sanchez F.
        • Brache V.
        • Jackanicz T.
        • Faundes A.
        Evaluation of four different contraceptive vaginal rings: steroid serum levels, luteal activity, bleeding control and lipid profiles.
        Contraception. 1992; 46: 387-398
        • Mishell Jr., D.
        • Lumkin M.
        • Jackanicz T.
        Initial clinical studies of intravaginal rings containing norethindrone and norgestrel.
        Contraception. 1975; 12: 253-260
        • Ballagh S.
        • Mishell D.
        • Jackanicz T.
        • Lacarra M.
        • Eggena P.
        Dose-finding study of a contraceptive ring releasing norethindrone acetate/ethinyl estradiol.
        Contraception. 1994; 50: 535-549
        • Laurikka-Routti M.
        • Haukkamaa M.
        • Heikinheimo O.
        A contraceptive vaginal ring releasing EE and the progestin ST1435: bleeding control, serum steroid concentrations, serum lipids and serum chemistry.
        Contraception. 1990; 42: 111-120
        • Sivin I.
        • Mishell Jr., D.
        • Victor A.
        • et al.
        A multicenter study of levonorgestrel���estradiol contraceptive vaginal rings. I: Use effectiveness.
        Contraception. 1981; 24: 341-358
        • Sivin I.
        • Mishell Jr., D.
        • Victor A.
        • et al.
        A multicenter study of levonorgestrel���estradiol contraceptive vaginal rings. II: Subjective and objective measures of effects. An international comparative trial.
        Contraception. 1981; 24: 359-376
        • Brache V.
        • Mishell D.R.
        • Lahteenmaki P.
        • et al.
        Ovarian function during use of vaginal rings delivering three different doses of NES.
        Contraception. 2001; 63: 257-261
        • Massai R.
        • Diaz S.
        • Jackanicz T.
        • Croxatto H.B.
        Vaginal rings for contraception in lactating women.
        Steroids. 2000; 65: 703-707
        • Brache V.
        • Alvarez-Sanchez F.
        • Faundes A.
        • Jackanicz T.
        • Mishell Jr., D.R.
        • Lahteenmaki P.
        Progestin-only contraceptive rings.
        Steroids. 2000; 65: 687-691
        • Weisberg E.
        • Fraser I.S.
        • Mishell Jr., D.R.
        • Lacarra M.
        • Darney P.
        • Jackanicz T.M.
        A comparative study of two contraceptive vaginal rings releasing norethindrone acetate and differing doses of ethinyl estradiol.
        Contraception. 1999; 59: 305-310
        • Weisberg E.
        • Fraser I.S.
        • Lacarra M.
        • Mishell Jr., D.R.
        • Jackanicz T.
        Effect of different insertion regimens on side effects with a combination contraceptive vaginal ring.
        Contraception. 1997; 56: 233-239
        • Ballagh S.A.
        • Mishell Jr., D.R.
        • Lacarra M.
        • Shoupe D.
        • Jackanicz T.M.
        • Eggena P.
        A contraceptive vaginal ring releasing norethindrone acetate and ethinyl estradiol.
        Contraception. 1994; 50: 517-533
        • Fraser I.S.
        • Lacarra M.
        • Mishell Jr., D.R.
        • et al.
        Vaginal epithelial surface appearances in women using vaginal rings for contraception.
        Contraception. 2000; 61: 131-138
        • Haukkamaa M.
        • Laurikka-Routti M.
        • Heikinheimo O.
        • Moo-Young A.J.
        Contraception with subdermal implants releasing the progestin ST 1435: a dose-finding study.
        Contraception. 1992; 45: 49-55
        • Diaz S.
        • Schiappacasse V.
        • Pavez M.
        • et al.
        Clinical trial with NES subdermal contraceptive implants.
        Contraception. 1995; 51: 33-38
        • Odlind V.
        • Lithell H.
        • Selinus I.
        • Vessby B.
        Unaltered lipoprotein and carbohydrate metabolism during treatment with contraceptive subdermal implants containing ST 1435.
        Contraception. 1985; 31: 123-130
        • Sivin I.
        • Croxatto H.B.
        • BahamondeL
        • et al.
        Two-year performance of a Nestorone��-releasing contraceptive implant: a three-center study of 300 women.
        Contraception. 2004; 69: 137-144
        • Croxatto H.B.
        • Zepeda A.
        Transdermal contraceptive systems: innovative technology for the twenty-first century.
        in: Sitruk-Ware R. Bardin C.W. Newer pharmacological agents, devices and delivery systems. Contraception. M. Dekker Inc., New York1992: 101-115
        • Sitruk-Ware R.
        Transdermal application of steroid hormones for contraception.
        J. Steroid Biochem. Mol. Biol. 1995; 53: 247-251
        • Kumar N.
        • Koide S.S.
        • Tsong Y.
        • Sundaram K.
        Nestorone��: a progestin with a unique pharmacological profile.
        Steroids. 2000; 65: 629-636
        • World Health Organization Global Programme on AIDS
        WHO manual for the standardization of colposcopy for the evaluation of vaginally administered products.
        in: WHO, Geneva1996: 15
        • Lahteenmaki P.L.A.
        • Hammond G.L.
        • Luukkainen T.
        Serum non-protein bound percentage and distribution of the progestin ST1435: no effect of ST 1435 treatment on plasma SHBG and CBG binding capacities.
        Acta Endoringinol. 1983; 102: 307-313
        • Heikinhemo O.
        • No�� G.
        • Haukkamaa M.
        • L��hteenm��ki P.
        The progestin ST 1435���rapid metabolism in man.
        Contraception. 1994; 50: 275-289
        • Price T.M.
        • Dupuis R.E.
        • Carr B.R.
        • Stanczyk F.Z.
        • Lobo R.A.
        • Droegemueller W.
        Single and multiple dose pharmacokinetics of a low dose oral contraceptive in women with chronic renal failure undergoing peritoneal dialysis.
        Am. J. Obstet. Gynecol. 1993; 168: 1400-1406